Skip to main content
. 2011 Sep 25;2012:960318. doi: 10.1155/2012/960318

Table 1.

Anthropometric and clinical characteristics of the study populations.

Characteristics Phase 1 Phase 2
Type 2 diabetes patients Control Subjects Type 2 diabetes Patients Control Subjects
N (Men/Women) 1019 (592/427) 1006 (606/400) 1047 (619/428) 1038 (516/522)
Age (years) 53 (45–62) 50 (44–60) 55 (49–62) 54 (45–64)
BMI (Kg/m2)
Men 23.80 (22.00–26.00) 23.10 (20.10–5.70) 24.82 (22.68–27.76) 24.68 (22.35–27.39)
Women 26.70 (24.20–29.20) 25.00 (21.10–8.50) 27.39 (24.56–30.63) 26.37 (23.13–29.33)
WHR
Men 1.00 (0.97–1.03) 0.97 (0.92–1.0) 0.98 (0.95–1.03) 0.97 (0.93–1.01)
Women 1.00 (0.97–1.03) 0.86 (0.82–0.92) 0.93 (0.87–0.97) 0.86 (0.82–0.90)
Systolic BP (mmHg) 130 (130–140) 120 (112–132) 130 (122–140) 130 (120–140)
Diastolic BP (mmHg) 80 (78–90) 80 (70–88) 82 (80–90) 80 (78–90)
HbA1c (%) 7.80 (6.50–9.40) 5.20 (4.90–5.60) 8.20 (6.90–9.60) 5.65 (5.33–5.89)
FPG (mmol/L) 7.90 (6.40–10.30) 4.90 (4.50–5.30) 7.79 (6.21–10.27) 4.87 (4.43–5.27)
2h PPG (mmol/L) 5.57 (4.83–6.30) 5.63 (4.88–6.22)
FPI (pmol/L) 82.80 (42.0–166.80) 32.40 (17.40–57.60) 74.40 (26.00–96.00) 43.80 (28.20–63.60)
HOMA-IR 5.20 (2.30–9.60) 1.20 (0.60–2.00) 4.30 (2.30–9.30) 1.60 (1.00–2.40)
HOMA-B 60.25 (25.3–154.51) 73.40 (40.70–138.60) 61.66 (25.61–131.86) 105.27 (65.13–167.32)
HOMA-S 0.20 (0.10–0.46) 0.86 (0.49–1.69) 0.23 (0.11–0.44) 0.64 (0.42–1.03)
C-peptide (nmol/L) 0.89 (0.56–1.36) 0.53 (0.36–0.73) 1.05 (0.69–1.60) 0.66 (0.50–0.86)
CRP (mg/L) 2.20 (0.90–4.70) 1.30 (0.60–3.00) 1.86 (0.90–3.44) 1.61 (0.90–3.04)
TC (mmol/L) 4.20 (3.50–5.00) 4.40 (3.7–5.10) 4.64 (3.86–5.42) 4.91 (4.22–5.52)
LDL-C (mmol/L) 2.57 (1.99–3.36) 2.79 (2.33–3.41) 2.73 (2.10–3.42) 3.01 (2.49–3.51)
HDL-C (mmol/L) 1.03 (0.88–1.22) 1.06 (0.88–1.28) 1.11 (0.94–1.34) 1.24 (1.06–1.46)
TG (mmol/L) 1.60 (1.10–2.20) 1.30 (1.00–1.80) 1.43 (0.98–2.13) 1.22 (0.86–1.64)

Values provided are median (interquartile range).

N: number of individuals, BMI: body mass index, WHR: waist to hip ratio, BP: blood pressure, HbA1c: glycosylated haemoglobin 1c, FPG: fasting plasma glucose, 2h PPG: 2h postload plasma glucose, FPI: fasting plasma insulin, HOMA-IR: homeostasis model assessments of insulin resistance, HOMA-B: homeostasis model assessments for β-cell function, HOMA-S: homeostasis model assessments for insulin sensitivity, CRP: C-reactive protein, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein-cholesterol, TG: triglyceride.